JP2024041747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024041747A5 JP2024041747A5 JP2023202447A JP2023202447A JP2024041747A5 JP 2024041747 A5 JP2024041747 A5 JP 2024041747A5 JP 2023202447 A JP2023202447 A JP 2023202447A JP 2023202447 A JP2023202447 A JP 2023202447A JP 2024041747 A5 JP2024041747 A5 JP 2024041747A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- expression vector
- recombinant expression
- amino acid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0039476 | 2020-03-31 | ||
| KR20200039476 | 2020-03-31 | ||
| JP2022559531A JP7846627B2 (ja) | 2020-03-31 | 2021-03-31 | 新規な免疫活性インターロイキン2アナログ |
| PCT/KR2021/004028 WO2021201615A1 (ko) | 2020-03-31 | 2021-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559531A Division JP7846627B2 (ja) | 2020-03-31 | 2021-03-31 | 新規な免疫活性インターロイキン2アナログ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024041747A JP2024041747A (ja) | 2024-03-27 |
| JP2024041747A5 true JP2024041747A5 (cg-RX-API-DMAC7.html) | 2026-04-20 |
Family
ID=77930406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559531A Active JP7846627B2 (ja) | 2020-03-31 | 2021-03-31 | 新規な免疫活性インターロイキン2アナログ |
| JP2023202447A Pending JP2024041747A (ja) | 2020-03-31 | 2023-11-30 | 新規な免疫活性インターロイキン2アナログ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559531A Active JP7846627B2 (ja) | 2020-03-31 | 2021-03-31 | 新規な免疫活性インターロイキン2アナログ |
Country Status (17)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121713A1 (es) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
| KR102445492B1 (ko) * | 2021-12-24 | 2022-09-21 | 엔케이젠 주식회사 | 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법 |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| IL317511A (en) | 2022-06-16 | 2025-02-01 | Cephalon Llc | IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses |
| CN119790064A (zh) * | 2022-08-23 | 2025-04-08 | 马斯得生物有限公司 | Il2变体和包括该il2变体的蛋白复合体 |
| KR20250126198A (ko) | 2024-02-15 | 2025-08-25 | 한림대학교 산학협력단 | 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3285989A (en) * | 1987-11-25 | 1989-06-14 | Cetus Corporation | Treatment of infections caused by a primary immunodeficiency with interleukin-2 |
| AU627477B2 (en) * | 1988-07-05 | 1992-08-27 | Amgen, Inc. | Interleukin ii analogs |
| CA2019714A1 (en) | 1989-06-27 | 1990-12-27 | Richard A. Chizzonite | Process for the determination of interleukins |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| CZ305123B6 (cs) * | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| AU2007201663A1 (en) | 2007-04-16 | 2008-10-30 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| KR20140106452A (ko) | 2013-02-26 | 2014-09-03 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| MY186251A (en) | 2014-01-20 | 2021-06-30 | Hanmi Pharm Ind Co Ltd | Long-acting insulin and use thereof |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| CN107148279B (zh) | 2014-10-21 | 2021-09-03 | 赛生药品股份国际有限公司 | 用免疫刺激剂治疗癌症 |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| KR20160134989A (ko) | 2015-05-14 | 2016-11-24 | 순천향대학교 산학협력단 | 인간 인터류킨-2 단백질을 포함하는 약학조성물 |
| CN107266553A (zh) * | 2016-04-08 | 2017-10-20 | 南京康志制药有限公司 | 高效人白细胞介素ⅱ突变体融合蛋白及其应用 |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| JP7356726B2 (ja) * | 2017-09-25 | 2023-10-05 | ディンフー バイオターゲット カンパニー リミテッド | タンパク性ヘテロ二量体及びその使用 |
| US10946068B2 (en) * | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7534215B2 (ja) * | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| CN108503714A (zh) | 2018-04-10 | 2018-09-07 | 浙江科途医学科技有限公司 | 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用 |
| MX2020012251A (es) * | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| AU2019288496B2 (en) * | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| SG11202005873QA (en) * | 2018-09-17 | 2020-07-29 | Gi Innovation Inc | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| MX2021005708A (es) * | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| US20220025007A1 (en) * | 2018-12-21 | 2022-01-27 | Hanmi Pharm. Co., Ltd. | Novel immunosuppressive interleukin 2 |
| CN111944036B (zh) | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| CN114437198A (zh) | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| BR112022017656A2 (pt) | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| AR121713A1 (es) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
-
2021
- 2021-03-31 AR ARP210100815A patent/AR121713A1/es unknown
- 2021-03-31 TW TW110111922A patent/TWI876021B/zh active
- 2021-03-31 BR BR112022018730A patent/BR112022018730A2/pt unknown
- 2021-03-31 CA CA3266069A patent/CA3266069A1/en active Pending
- 2021-03-31 KR KR1020210042319A patent/KR102545250B1/ko active Active
- 2021-03-31 CN CN202180025732.4A patent/CN115427437B/zh active Active
- 2021-03-31 JP JP2022559531A patent/JP7846627B2/ja active Active
- 2021-03-31 EP EP21781220.5A patent/EP4130027A4/en active Pending
- 2021-03-31 NZ NZ793819A patent/NZ793819A/en unknown
- 2021-03-31 CA CA3169564A patent/CA3169564C/en active Active
- 2021-03-31 PE PE2022001948A patent/PE20221759A1/es unknown
- 2021-03-31 US US17/915,808 patent/US11746137B2/en active Active
- 2021-03-31 IL IL295826A patent/IL295826B2/en unknown
- 2021-03-31 MX MX2022011893A patent/MX2022011893A/es unknown
- 2021-03-31 AU AU2021202825A patent/AU2021202825B2/en active Active
- 2021-03-31 CN CN202410385677.5A patent/CN118271419A/zh active Pending
- 2021-03-31 WO PCT/KR2021/004028 patent/WO2021201615A1/ko not_active Ceased
-
2022
- 2022-06-02 AU AU2022203841A patent/AU2022203841A1/en not_active Abandoned
- 2022-08-26 ZA ZA2022/09565A patent/ZA202209565B/en unknown
- 2022-09-21 CL CL2022002562A patent/CL2022002562A1/es unknown
-
2023
- 2023-06-09 KR KR1020230074093A patent/KR102946368B1/ko active Active
- 2023-07-10 US US18/349,656 patent/US12415842B2/en active Active
- 2023-11-30 JP JP2023202447A patent/JP2024041747A/ja active Pending
-
2026
- 2026-04-07 CL CL2026001105A patent/CL2026001105A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019122392A5 (cg-RX-API-DMAC7.html) | ||
| EP4272765A3 (en) | Adeno-associated virus (aav) clade f vector and uses therefor | |
| JP2023082054A5 (cg-RX-API-DMAC7.html) | ||
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| JP2023179457A5 (cg-RX-API-DMAC7.html) | ||
| JP2014224126A5 (cg-RX-API-DMAC7.html) | ||
| JP2017212998A5 (cg-RX-API-DMAC7.html) | ||
| JP2010222379A5 (cg-RX-API-DMAC7.html) | ||
| NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2021505201A5 (cg-RX-API-DMAC7.html) | ||
| NZ597685A (en) | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli | |
| JP2015525217A5 (cg-RX-API-DMAC7.html) | ||
| FI3737399T3 (fi) | ATF5-peptidivariantit ja niiden käytöt | |
| NZ596764A (en) | N-glycan core beta-galactosyltransferase and uses thereof | |
| MX2021004714A (es) | Proteina cas9 modificada, y uso de la misma. | |
| JP2020513810A5 (cg-RX-API-DMAC7.html) | ||
| EP4616705A3 (en) | Peronospora resistance in spinacia oleracea | |
| JP2024530926A5 (cg-RX-API-DMAC7.html) | ||
| JP2014193147A5 (cg-RX-API-DMAC7.html) | ||
| WO2007142582A8 (en) | Fluorescent proteins and genes encoding them | |
| EP1482047A4 (en) | PROTEIN OR POLYPEPTIDE HAVING LACRYMOGENIC SUBSTANCE SYNTHASE ACTIVITY, DNA ENCODING THE PROTEIN OR THE POLYPEPTIDE, PROCESS FOR OBTAINING SAID PROTEIN OR POLYPEPTIDE, AND MOLECULE OF NUCLEIC ACIDS INHIBITING THE TRANSLATION OF MESSENGER RNA RELATING TO THE PROTEIN OR POLYPEPTIDE THE PEPTIDE | |
| JP2003334088A5 (cg-RX-API-DMAC7.html) | ||
| JP2008517998A5 (cg-RX-API-DMAC7.html) | ||
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| JP2012507278A5 (cg-RX-API-DMAC7.html) |